Date: 09-03-2023
Your Name: Zijian Chen
Manuscript Title: <u>Integrative learning in developing an immunologic lncRNA signature as a consensu</u>
risk-stratification tool for lung adenocarcinoma.
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	Zijian Chen has nothing to disclose
2	Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses	Time frame: past None None	Zijian Chen has nothing to disclose  Zijian Chen has nothing to disclose
4	Consulting fees		Zijian Chen has nothing to disclose

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	None	Zijian Chen has nothing to disclose  Zijian Chen has nothing to disclose
7	Support for attending meetings and/or travel	None	Zijian Chen has nothing to disclose
8	Patents planned, issued or pending	_ <u>√</u> None	Zijian Chen has nothing to disclose
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	Zijian Chen has nothing to disclose
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_√ None	Zijian Chen has nothing to disclose
11	Stock or stock options	None	Zijian Chen has nothing to disclose
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	Zijian Chen has nothing to disclose
13	Other financial or non- financial interests	_√None	Zijian Chen has nothing to disclose

Zijian Chen has nothing to disclose.	

Please place an "X" next to the following statement to indicate your agreement:

Date: 20-J	Jan-2023
Your Name:	: Yangqi Liu
Manuscript <sup>1</sup>	t Title: Integrative learning in developing an immunologic lncRNA signature as a consensus
risk-stratif	fication tool for lung adenocarcinoma.
Manuscrint	number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_√ None	Yangqi Liu has nothing to disclose
3	Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses	Time frame: past None None	Yangqi Liu has nothing to disclose  Yangqi Liu has nothing to disclose
4	Consulting fees	None	Yangqi Liu has nothing to disclose

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert testimony	None None	Yangqi Liu has nothing to disclose  Yangqi Liu has nothing to disclose
7	Support for attending meetings and/or travel	_√ None	Yangqi Liu has nothing to disclose
8	Patents planned, issued or pending	None	Yangqi Liu has nothing to disclose
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	Yangqi Liu has nothing to disclose
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_√None	Yangqi Liu has nothing to disclose
11	Stock or stock options	_√None	Yangqi Liu has nothing to disclose
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_√_None	Yangqi Liu has nothing to disclose
13	Other financial or non- financial interests	_√ None	Yangqi Liu has nothing to disclose

Yangqi Liu has nothing to disclose.		

Please place an "X" next to the following statement to indicate your agreement:

Date:2	20-Jan-2023
Your Na	me: Changhong Wan
Manusc	ript Title: <u>Integrative learning in developing an immunologic lncRNA signature as a consensus</u>
risk-str	ratification tool for lung adenocarcinoma.
Manusc	ript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	Changhong Wan has nothing to disclose
		Time frame: past	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	Changhong Wan has nothing to disclose
3	Royalties or licenses	None	Changhong Wan has nothing to disclose
4	Consulting fees	None	Changhong Wan has nothing to disclose

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert testimony	_√ None	Changhong Wan has nothing to disclose  Changhong Wan has nothing to disclose
7	Support for attending meetings and/or travel	_√ None	Changhong Wan has nothing to disclose
8	Patents planned, issued or pending	None	Changhong Wan has nothing to disclose
9	Participation on a Data Safety Monitoring Board or Advisory Board	_√_None	Changhong Wan has nothing to disclose
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_√ None	Changhong Wan has nothing to disclose
11	Stock or stock options	_√_None	Changhong Wan has nothing to disclose
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	Changhong Wan has nothing to disclose
13	Other financial or non- financial interests	_√_None	Changhong Wan has nothing to disclose

Changhong Wan has nothing	to disclose.		

Please place an "X" next to the following statement to indicate your agreement:

Date: 20-Jan-2023	
Your Name: Weizhe Huang	
Manuscript Title: <u>Integrative learning in developing</u>	an immunologic lncRNA signature as a consensus
risk-stratification tool for lung adenocarcinoma.	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_√None	Weizhe Huang has nothing to disclose
3	Grants or contracts from any entity (if not indicated in item #1 above).  Royalties or licenses	Time frame: past None None	36 months  Weizhe Huang has nothing to disclose  Weizhe Huang has nothing to disclose
4	Consulting fees	None	Weizhe Huang has nothing to disclose

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events  Payment for expert	_√_None	Weizhe Huang has nothing to disclose  Weizhe Huang has nothing to disclose
	testimony		
7	Support for attending meetings and/or travel	_√ None	Weizhe Huang has nothing to disclose
8	Patents planned, issued or pending	_√None	Weizhe Huang has nothing to disclose
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	Weizhe Huang has nothing to disclose
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_√ None	Weizhe Huang has nothing to disclose
11	Stock or stock options	_√ None	Weizhe Huang has nothing to disclose
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_√None	Weizhe Huang has nothing to disclose
13	Other financial or non- financial interests	None	Weizhe Huang has nothing to disclose

Weizhe Huang has nothing to disclose.				

Please place an "X" next to the following statement to indicate your agreement: